Drug Efficacy Monitoring via Serial Imaging Automation Workflow

Manual lesion measurement and RECIST/WHO criteria application are rate-limiting steps in oncology trials. A custom workflow automates segmentation, volumetric analysis, and criteria scoring across serial scans, compressing the imaging analysis timeline from manual batch processing to continuous, near-real-time assessment. This directly shortens the data lock period, enabling faster go/no-go decisions and earlier regulatory submissions.

Imaging Contract Research Organizations (CROs) face high labor costs for radiologist contouring and data management. Automating lesion segmentation, change detection, and data export to EDC systems (e.g., Medidata Rave, Oracle Clinical) eliminates the majority of repetitive manual work. The savings translate directly to lower per-patient imaging costs for sponsors and improved margin for CROs, while reallocating expert labor to quality oversight and complex case adjudication.

Manual lesion measurement introduces inter- and intra-reader variability, which can obscure true drug signal and increase trial noise. An automated, rule-based workflow applies identical segmentation algorithms and response criteria (RECIST 1.1, iRECIST) across all timepoints and patients. This standardization improves data quality, increases statistical power, and provides a more reliable, auditable basis for regulatory evaluation.

Maintaining blinding and centralizing image review across global sites is operationally complex. A custom workflow ingests anonymized DICOMs from site PACS/VNAs, routes them through automated QC and segmentation agents, and stores results in a blinded analysis database. This architecture ensures consistent, unbiased endpoint assessment across hundreds of trial sites, mitigating site-based interpretation drift and simplifying audit trails for regulators.

Beyond simple diameter, advanced biomarkers like tumor volume, texture, and perfusion require complex 3D analysis impractical at scale manually. This workflow operationalizes these quantitative endpoints by orchestrating specialized segmentation models (e.g., nnU-Net, MONAI), calculating biomarkers, and piping results into downstream analytics. This turns exploratory imaging science into a reliable, high-throughput operational asset for precision medicine trials.

Regulators require transparency into imaging analysis methods and human oversight. The workflow architecture embeds governance by design: all automated segmentations receive a confidence score, with low-confidence results routed for radiologist review. Every override is logged, and the full pipeline—from DICOM ingestion to EDC export—is version-controlled and documented. This creates a defensible, 21 CFR Part 11-compliant process that reduces submission risk.

The central agent that ingests anonymized serial DICOM studies from the trial's imaging core lab, enforces blinding protocols, and coordinates the entire segmentation and measurement pipeline. It manages study versioning, handles missing timepoints, and ensures traceability for audit. Integration with clinical trial management systems (CTMS) allows for automated status updates and discrepancy flagging.

A specialized, modality-aware agent that loads pre-trained segmentation models (e.g., nnUNet, MONAI) to automatically contour target lesions identified by radiologists at baseline. It performs 3D volumetric analysis on follow-up scans, calculating the sum of diameters (for RECIST) or total volume (for volumetric criteria). This agent includes post-processing logic to handle imaging artifacts and outputs structured JSON with confidence scores for each measurement.

A rules-based agent that applies clinical trial protocol definitions (RECIST 1.1, WHO, iRECIST) to the quantitative data. It classifies patient response as Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD). The engine handles complex edge cases like non-target lesions and new lesions, and generates the required data points for the electronic data capture (EDC) system, such as SLD_PERCENT_CHANGE and BEST_OVERALL_RESPONSE.

This system component manages the secure, validated transfer of response data from the analysis pipeline to the sponsor's EDC (e.g., Medidata Rave, Oracle Clinical). It formats data according to the trial's specific case report form (CRF) specifications, performs pre-submission validation checks, and handles rejection/query responses from the EDC. It maintains a full, immutable audit log of all data transmissions for regulatory inspection.

A human-in-the-loop interface that routes low-confidence segmentations, protocol deviations, and all baseline lesion identifications to a designated radiologist for review. Integrated directly into the radiologist's clinical PACS or a zero-footprint web viewer, it allows for efficient overrides and annotations. All changes are logged, creating a gold-standard dataset for continuous model retraining and providing the necessary clinical oversight for regulatory acceptance.

An operational agent that continuously monitors the segmentation model's performance against a held-out set of expert-annotated studies. It tracks metrics like Dice score and Hausdorff distance, alerting the MLOps team to performance drift caused by changes in scanner hardware or imaging protocols. This agent can trigger automated retraining pipelines, ensuring the workflow's analytical validity throughout the multi-year duration of a Phase III trial.